Abstract Background: The docetaxel–carboplatin–trastuzumab–pertuzumab (TCbHP) regimen is widely used as a standard neoadjuvant strategy for HER2-positive breast cancer and provides substantial pathologic complete response (pCR) benefits. However, evidence on the optimal balance between treatment efficacy and toxicity remains limited.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Binbin
Contact Binbin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack